CD47 and anemia: Importantly, the intratumoral delivery of mCD47nb-Fc by the adenovirus vector did not cause severe anemia, thrombocytopenia, and other adverse events often seen with macrophage-mediated cellular phagocytosis after the systemic administration of anti-CD47 agents.